Publicly quoted biotech companies increasingly rely on private investors to raise money
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
IPO floodgates unlikely to open after Ark floatation
IPO plans sour on both sides of the pond
Related external links
Rights and permissions
About this article
Cite this article
Mitchell, P. Cash-strapped biotechs find financing alternative. Nat Biotechnol 22, 1057–1058 (2004). https://doi.org/10.1038/nbt0904-1057
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0904-1057
This article is cited by
-
Erratum: Cash-strapped biotechs find financing alternative
Nature Biotechnology (2004)